9 research outputs found
Corneal confocal microscopy detects a reduction in corneal endothelial cells and nerve fibres in patients with acute ischemic stroke
YesEndothelial dysfunction and damage underlie cerebrovascular disease and ischemic stroke. We
undertook corneal confocal microscopy (CCM) to quantify corneal endothelial cell and nerve
morphology in 146 patients with an acute ischemic stroke and 18 age-matched healthy control
participants. Corneal endothelial cell density was lower (P<0.001) and endothelial cell area (P<0.001)
and perimeter (P<0.001) were higher, whilst corneal nerve fbre density (P<0.001), corneal nerve
branch density (P<0.001) and corneal nerve fbre length (P=0.001) were lower in patients with acute
ischemic stroke compared to controls. Corneal endothelial cell density, cell area and cell perimeter
correlated with corneal nerve fber density (P=0.033, P=0.014, P=0.011) and length (P=0.017,
P=0.013, P=0.008), respectively. Multiple linear regression analysis showed a signifcant independent
association between corneal endothelial cell density, area and perimeter with acute ischemic stroke
and triglycerides. CCM is a rapid non-invasive ophthalmic imaging technique, which could be used to
identify patients at risk of acute ischemic stroke.Qatar National Research Fund Grant BMRP2003865
Epigenetics in renal cell cancer: mechanisms and clinical applications
Renal cell carcinoma (RCC) is characterized by an infrequent number of somatic mutations. By contrast, epigenetic aberrations are commonly found in RCC, indicating that epigenetic reprogramming is an important event in RCC development. Epigenetic alterations comprise several different aberrations, such as changes in histone modifications, DNA methylation, and microRNA levels, and occur in the most important signalling pathways in RCC, such as the von Hippel-Lindau disease tumour suppressor (VHL)-hypoxia-inducible factor (HIF) pathway, the WNT-beta-catenin pathway, and pathways involved in epithelial-mesenchymal transition. Owing to their involvement in these pathways and frequent occurrence in RCC, epigenetic alterations are regarded as potential biomarkers for the early detection of disease and for prediction of prognosis and treatment response. In addition, most of these alterations are potentially reversible, so they also provide new targets for therapy. At the moment, epigenetic biomarkers for RCC are not being used in clinical practice, but targeted epigenetic therapies are under investigation. Understanding the extent of epigenetic changes occurring in RCC and the mechanisms by which they influence disease progression and treatment response, as well as knowledge of current research on biomarkers and treatments, is crucial to successful clinical translation of epigenetics in RCC